These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34337428)

  • 21. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer.
    Sundar R; Huang KK; Qamra A; Kim KM; Kim ST; Kang WK; Tan ALK; Lee J; Tan P
    Ann Oncol; 2019 Mar; 30(3):424-430. PubMed ID: 30624548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Senescence markers: Predictive for response to checkpoint inhibitors.
    Moreira A; Gross S; Kirchberger MC; Erdmann M; Schuler G; Heinzerling L
    Int J Cancer; 2019 Mar; 144(5):1147-1150. PubMed ID: 30151962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Pan M; Alavi M; Herrinton LJ
    Perm J; 2018; 22():17-149. PubMed ID: 29616914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
    Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of senescence biomarkers in rheumatoid arthritis: relevance to disease progression.
    Petersen LE; Schuch JB; de Azeredo LA; Baptista TSA; Motta JG; do Prado AD; Bauer ME
    Clin Rheumatol; 2019 Oct; 38(10):2909-2915. PubMed ID: 31187337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
    Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma.
    Hurkmans DP; Jensen C; Koolen SLW; Aerts J; Karsdal MA; Mathijssen RHJ; Willumsen N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 33. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
    Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
    Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
    Front Oncol; 2021; 11():658690. PubMed ID: 34150625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients.
    Machiraju D; Wiecken M; Lang N; Hülsmeyer I; Roth J; Schank TE; Eurich R; Halama N; Enk A; Hassel JC
    Oncoimmunology; 2021 May; 10(1):1926762. PubMed ID: 34104542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
    Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
    Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
    Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
    Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.